MEDULLARY THYROID CANCER

This adverse event was reported 340 times

These drugs are most commonly taken by patients reporting MEDULLARY THYROID CANCER:

# Drug Count
0 ORAL SEMAGLUTIDE 63
1 LIRAGLUTIDE 42
2 TIRZEPATIDE 36
3 METFORMIN 35
4 METFORMIN ER 500 MG 33
5 METFORMIN ER 750 MG 33
6 EXENATIDE 22
7 DULAGLUTIDE 21
8 INSULIN GLARGINE 20
9 LEVOTHYROXINE SODIUM 16
See all common drugs associated with MEDULLARY THYROID CANCER

MEDULLARY THYROID CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 VANDETANIB 10 0.0055
1 INSULIN DEGLUDEC AND LIRAGLUTIDE 2 0.0012
2 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE 2 0.0010
3 LIRAGLUTIDE 42 0.0008
4 ORAL SEMAGLUTIDE 63 0.0008
5 FLUOROMETHOLONE 2 0.0006
6 EXENATIDE 22 0.0004
7 MIFEPRISTONE 2 0.0004
8 ALFUZOSIN HYDROCHLORIDE 1 0.0004
9 ALENDRONATE SODIUM AND CHOLECALCIFEROL 1 0.0004
See all drugs enriched for association with MEDULLARY THYROID CANCER

MEDULLARY THYROID CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 1 0.0015
1 Progestin Antagonist [EPC] 2 0.0004
2 GLP-1 Receptor Agonist [EPC] 175 0.0004
3 Provitamin D2 Compound [EPC] 9 0.0003
4 Dipeptidyl Peptidase 4 Inhibitor [EPC] 7 0.0002
5 Vitamin D3 Analog [EPC] 4 0.0002
6 Sulfonylurea [EPC] 18 0.0001
7 Somatostatin Analog [EPC] 1 0.0001
8 Insulin [EPC] 6 0.0001
9 Cephalosporin Antibacterial [EPC] 1 0.0001
See all drug classes enriched for association with MEDULLARY THYROID CANCER